News

KYV-101 helps 2 hard-to-treat progressive MS patients: Case study

Kyverna Therapeutics‘ cell-based therapy KYV-101 had an acceptable safety profile and promising treatment effects when given to two people with hard-to-treat progressive multiple sclerosis (MS), according to a case study. “We are very pleased about offering this potentially paradigm-shifting treatment opportunity to patients that have exhausted other medical…

Juvisé to market, develop Ponvory outside North America

The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The global rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine.

Early high-efficacy MS treatment recommended for young patients

High-efficacy therapies given early can significantly reduce the risk of disability worsening in children and adolescents with multiple sclerosis (MS), particularly when treatment is started while patients have fairly minimal disability, according to a new study. While lower-efficacy therapies were also associated with a reduced risk of disability progression…

BCG vaccine to prevent tuberculosis not linked to MS risk: Study

Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) or having latent (inactive) TB in young adulthood aren’t linked to the risk of developing multiple sclerosis (MS), a Norwegian study found. The study, “BCG vaccination and multiple sclerosis risk: A Norwegian cohort study,” was published in…

Smartphone, wearable device data found reliable to monitor MS: Study

Measurements from smartphones and wearable devices like smartwatches can reliably provide clinically meaningful data to monitor multiple sclerosis (MS), a new study from Switzerland reports. While daily data from such devices did not prove sufficiently reliable in this small study, information generated weekly — across more than 45 different…

Restoring ‘lost’ pathway of neuroprotection benefits MS mice

Treatment with the neuroprotective protein HB-EGF eased inflammation and promoted tissue recovery across various disease stages in a multiple sclerosis (MS) mouse model, recent research suggests. Researchers found that HB-EGF is produced by astrocytes, a type of nerve support cell, to ease acute inflammation early on, but this protective…

Eye tracking device for monitoring MS severity approved in Canada

Health Canada has approved the commercial use of ETNA-MS, a software-based medical device that uses eye tracking to noninvasively measure disease severity in people with multiple sclerosis (MS). Short for Eye-Tracking Neurological Assessment for Multiple Sclerosis, ETNA-MS assesses disease severity based on a person’s eye movements. It’s intended for…

Exposure to household chemicals harms myelin-making cells

Two types of chemicals in household disinfectants and furniture can disrupt the development of oligodendrocytes, the brain cells chiefly responsible for making myelin, a new study shows. The finding suggests that exposure to these chemicals may be a risk factor for disorders related to myelin such as…

SetPoint nerve stimulator for RRMS accepted to FDA TAP program

The U.S. Food and Drug Administration (FDA) has accepted SetPoint Medical, which is developing a nerve stimulator for people with relapsing-remitting multiple sclerosis (RRMS), into a pilot program designed to promote the development of new medical devices, the company said. The Total Product Life Cycle Advisory Program…

Unmet MS care needs prevalent among patients in Italy: Survey

Almost all of the nearly 700 people with multiple sclerosis (MS) in Italy who responded to a patient survey reported at least one unmet MS care need — ranging from insufficient access to primary care, social interactions, assistance, doctor-patient relationships, and information about the neurodegenerative disease. More than half…

Seqster data-sharing platform selected to power MSAA network

Note: This story was updated March 26, 2024, to correct the affiliations of the Multiple Sclerosis Implementation Network staff and to note changes to the program’s partners. The Multiple Sclerosis Association of America (MSAA) has tapped healthcare technology company Seqster to power its multicenter research and learning program, which…

S1PR modulators linked to seizure risk in MS trial meta-analysis

People with multiple sclerosis (MS) have a twofold higher risk of seizures compared with the general population, according to pooled data from clinical trials. Among MS patients, treatment with sphingosine-1-phosphate receptor (S1PR) modulators, a class of MS disease-modifying therapies (DMTs) that includes the oral medications Gilenya (fingolimod),…

Neurostimulator to repair myelin in RRMS named breakthrough device

The U.S. Food and Drug Administration has designated SetPoint Medical’s neurostimulator a breakthrough device for the treatment of relapsing-remitting multiple sclerosis (RRMS). This designation is intended to accelerate the development of devices intending to more effectively treat or diagnose life-threatening or chronically debilitating diseases than standard approaches.

MSAA, Lumina partner to provide MRIs to MS patients in Ohio

Lumina Imaging has partnered with the Multiple Sclerosis Association of America (MSAA) to provide affordable brain and spinal cord MRI scans to multiple sclerosis (MS) patients. The partnership makes Lumina the preferred provider for the MSAA’s MRI Access Program in northeast Ohio. The program is designed…

Metabolon, Cardiff University partner for MS biomarker research

Metabolon and Cardiff University are partnering to discover new biomarkers that could help better understand disease mechanisms and develop new treatments for multiple sclerosis (MS). The project leverages Metabolon’s expertise in metabolomics, a field of research that measures all products of metabolism, called metabolites, that are made…